Surgeon seniority and experience have no effect on CaP detection rates using MRI/TRUS fusion-guided targeted biopsies
CONCLUSIONS: Urologist seniority is not associated with CDR, urologist experience tends to improve cancer detection, and CDR does not differ between the anterior and posterior regions of the prostate.PMID:38245408 | DOI:10.1016/j.urolonc.2023.11.007 (Source: Urologic Oncology)
Source: Urologic Oncology - January 20, 2024 Category: Urology & Nephrology Authors: Fayek Taha St éphane Larre Benjamin Branchu ReSurg Source Type: research
Simplified cardiovascular index may be the best comorbidity index for clinical use in prediction of mortality for renal cancer patients
CONCLUSION: Increasing comorbidity, age, tumor size, and cM stage are predictors of ACM for suspected renal cancer patients. CVI appears to provide comparable information to various iterations of CCI (uCCI, aCCI) while being the simplest to use. Utilization of CVI may assist clinicians and patients when considering between interventional and noninterventional approaches for suspected renal cancer.PMID:38242826 | DOI:10.1016/j.urolonc.2024.01.004 (Source: Urologic Oncology)
Source: Urologic Oncology - January 19, 2024 Category: Urology & Nephrology Authors: Dennis Boynton Sabrina L Noyes Adharsh Murali Henry Peabody Andrew Krumm Karandeep Singh Brian R Lane Source Type: research
Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes
CONCLUSIONS: A longer TTRC is associated with worse oncological outcomes in patients treated with NAC and RC.PMID:38238116 | DOI:10.1016/j.urolonc.2023.12.014 (Source: Urologic Oncology)
Source: Urologic Oncology - January 18, 2024 Category: Urology & Nephrology Authors: Siberyn T Nuijens Frits H M van Osch Lisa M C van Hoogstraten J Alfred Witjes Katja K H Aben Tom J N Hermans Source Type: research
Age related trends in the utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer
CONCLUSION: Rates of NAC use prior to RC have increased among all age groups with the lowest utilization rate among the elderly. NAC use was associated with greater pathologic downstaging in all age groups. These data show a promising trend in the uptake of the gold standard for treatment of MIBC; however, the underlying etiology of differing rates of NAC utilization remains to be determined.PMID:38238117 | DOI:10.1016/j.urolonc.2024.01.006 (Source: Urologic Oncology)
Source: Urologic Oncology - January 18, 2024 Category: Urology & Nephrology Authors: Abigail Kohut-Jackson Jeffrey Orf Dominic Barresi Facundo Davaro Zachary Hamilton Source Type: research
The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy
CONCLUSION: IDC-P on biopsy pathology was found to be an independent risk factor to predict a poor pathology response of primary CaP to neoadjuvant therapies.PMID:38233262 | DOI:10.1016/j.urolonc.2023.11.018 (Source: Urologic Oncology)
Source: Urologic Oncology - January 17, 2024 Category: Urology & Nephrology Authors: Binyu Wang Yao Fu Mengxia Chen Shan Peng Giancarlo Marra Junlong Zhuang Shiwei Zhang Hongqian Guo Xuefeng Qiu Source Type: research
Telemedicine in urologic oncology care: Will telemedicine exacerbate disparities?
CONCLUSION: The lower rates of telemedicine use among Black patients could exacerbate pre-existing disparities in prostate, bladder, and kidney cancer outcomes.PMID:38220521 | DOI:10.1016/j.urolonc.2023.10.002 (Source: Urologic Oncology)
Source: Urologic Oncology - January 14, 2024 Category: Urology & Nephrology Authors: Zeynep G Gul Danielle R Sharbaugh Chad Ellimoottil Kimberly J Rak Jonathan G Yabes Benjamin J Davies Bruce L Jacobs Source Type: research
Precision medicine for urothelial carcinoma: An international perspective
Urol Oncol. 2024 Jan 12:S1078-1439(23)00360-5. doi: 10.1016/j.urolonc.2023.11.008. Online ahead of print.ABSTRACTThe treatment landscape of urothelial cancers has evolved in the last decade with the approval of chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates. Although improvements in response and survival have been achieved with these strategies, in some scenarios their benefit is still questionable. Current efforts to identify prognostic and predictive biomarkers are crucial for better patient selection and treatment outcomes. In this paper we will review the most promising bio...
Source: Urologic Oncology - January 13, 2024 Category: Urology & Nephrology Authors: Mariane S Fontes Daniel Vargas Pivato de Almeida Flavio C árcano Paulo Lages Rodrigo Dienstmann Source Type: research
Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma
CONCLUSION: Based on OS and PFS, the lenvtatinib + everolimus combination yielded superior, followed by cabozantinib and Lenvatinib monotherapies; all were limited by a worse SAE profile. Nivolumab and pazopanib had the lowest odds of SAEs.PMID:38216444 | DOI:10.1016/j.urolonc.2023.12.002 (Source: Urologic Oncology)
Source: Urologic Oncology - January 12, 2024 Category: Urology & Nephrology Authors: Mavis Obeng-Kusi Jordyn J Kreutzfeldt Ricardo J Estrada-Mendizabal Briana M Choi Ivo Abraham Alejandro Recio-Boiles Source Type: research
Long-term outcomes of pelvic-fascia sparing robotic-assisted radical prostatectomy versus standard technique: Superior urinary function and quality of life without compromising oncologic efficacy in a single-surgeon series
CONCLUSIONS: PFS-RARP improves continence and patient-reported QOL up to 24 months postoperatively without compromising oncologic outcomes.PMID:38212151 | DOI:10.1016/j.urolonc.2023.11.020 (Source: Urologic Oncology)
Source: Urologic Oncology - January 11, 2024 Category: Urology & Nephrology Authors: Christopher P Dall J Bradley Mason Eshrar Choudhury Belen Mora-Garijo Jillian Egan Jim C Hu Keith J Kowalczyk Source Type: research
Is my patient with urothelial cancer (in)eligible for platinum?
Urol Oncol. 2024 Feb;42(2):27. doi: 10.1016/j.urolonc.2023.12.015. Epub 2024 Jan 8.NO ABSTRACTPMID:38195329 | DOI:10.1016/j.urolonc.2023.12.015 (Source: Urologic Oncology)
Source: Urologic Oncology - January 9, 2024 Category: Urology & Nephrology Authors: Irfan Karahan Burak Bilgin Source Type: research
Differences in cancer presentation, treatment, and mortality between rural and urban patients diagnosed with kidney cancer in the United States
CONCLUSIONS: Patients in RAs are more likely to present with advanced KCa at diagnosis compared to those in UAs and may also experience different treatment options including a lesser likelihood of undergoing partial nephrectomy. Rural patients with KCa also demonstrated significantly worse OS and CSS compared to their urban counterparts. Further patient-level studies are required to better understand the discrepancy in CSS between urban and rural patients diagnosed with KCa.PMID:38195330 | DOI:10.1016/j.urolonc.2023.12.011 (Source: Urologic Oncology)
Source: Urologic Oncology - January 9, 2024 Category: Urology & Nephrology Authors: Christopher Connors Micah Levy Chih Peng Chin Daniel Wang Olamide Omidele Francisca Larenas Michael Palese Source Type: research
Four score and 7 years ago: The discovery of acid phosphatase and the birth of prostate cancer biomarkers
Urol Oncol. 2024 Feb;42(2):25-26. doi: 10.1016/j.urolonc.2023.10.006. Epub 2024 Jan 6.NO ABSTRACTPMID:38185604 | DOI:10.1016/j.urolonc.2023.10.006 (Source: Urologic Oncology)
Source: Urologic Oncology - January 7, 2024 Category: Urology & Nephrology Authors: Kevin R Loughlin Source Type: research
Four score and 7 years ago: The discovery of acid phosphatase and the birth of prostate cancer biomarkers
Urol Oncol. 2024 Jan 6:S1078-1439(23)00339-3. doi: 10.1016/j.urolonc.2023.10.006. Online ahead of print.NO ABSTRACTPMID:38185604 | DOI:10.1016/j.urolonc.2023.10.006 (Source: Urologic Oncology)
Source: Urologic Oncology - January 7, 2024 Category: Urology & Nephrology Authors: Kevin R Loughlin Source Type: research
Four score and 7 years ago: The discovery of acid phosphatase and the birth of prostate cancer biomarkers
Urol Oncol. 2024 Jan 6:S1078-1439(23)00339-3. doi: 10.1016/j.urolonc.2023.10.006. Online ahead of print.NO ABSTRACTPMID:38185604 | DOI:10.1016/j.urolonc.2023.10.006 (Source: Urologic Oncology)
Source: Urologic Oncology - January 7, 2024 Category: Urology & Nephrology Authors: Kevin R Loughlin Source Type: research
Clinical significance of prostate cancer identified by transperineal standard template biopsy in men with nonsuspicious multiparametric magnetic resonance imaging
CONCLUSION: Within our cohort, false-negative rates of mpMRI for csCaP are substantial, reaching 15%. Nonsuspicious cases may contain a large volume tumor since the high GPC of SBx. For cases with nonsuspicious imaging and higher PSAD, a confirmatory biopsy may be necessary due to the increased risk of missed csCaP by mpMRI.PMID:38182499 | DOI:10.1016/j.urolonc.2023.11.004 (Source: Urologic Oncology)
Source: Urologic Oncology - January 5, 2024 Category: Urology & Nephrology Authors: Douglas M Dahl Shulin Wu Sharron X Lin Mengjie Hu Alfred A Barney Michelle M Kim Kristine M Cornejo Mukesh G Harisinghani Adam S Feldman Chin-Lee Wu Source Type: research
